M
Muzaffar H. Qazilbash
Researcher at University of Texas MD Anderson Cancer Center
Publications - 372
Citations - 7206
Muzaffar H. Qazilbash is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Transplantation & Hematopoietic stem cell transplantation. The author has an hindex of 38, co-authored 307 publications receiving 5968 citations. Previous affiliations of Muzaffar H. Qazilbash include University of Texas Health Science Center at Houston.
Papers
More filters
Journal ArticleDOI
Lenalidomide after stem-cell transplantation for multiple myeloma
Philip L. McCarthy,Kouros Owzar,Craig C. Hofmeister,David D. Hurd,Hani Hassoun,Paul G. Richardson,Sergio Giralt,Edward A. Stadtmauer,Daniel J. Weisdorf,Ravi Vij,Jan S. Moreb,Natalie S. Callander,Koen van Besien,Teresa Gentile,Luis Isola,Richard T. Maziarz,Don A. Gabriel,Asad Bashey,Heather Landau,Thomas G. Martin,Muzaffar H. Qazilbash,Denise Levitan,Brian McClune,Robert L. Schlossman,Vera Hars,John Postiglione,Chen Jiang,Elizabeth Bennett,Susan Barry,Linda Bressler,Michael Kelly,Michele Seiler,Cara A. Rosenbaum,Parameswaran Hari,Marcelo C. Pasquini,Mary M. Horowitz,Thomas C. Shea,Steven M. Devine,Kenneth C. Anderson,Charles A. Linker +39 more
TL;DR: Lenalidomide maintenance therapy, initiated at day 100 after hematopoietic stem-cell transplantation, was associated with more toxicity and second cancers but a significantly longer time to disease progression and significantly improved overall survival among patients with myeloma.
Journal ArticleDOI
Extracorporeal photochemotherapy for the treatment of steroid resistant chronic GVHD
Daniel R. Couriel,Chitra Hosing,Rima M. Saliba,Elizabeth J. Shpall,Paolo Anderlini,Beverly Rhodes,Veronica R. Smith,Issa F. Khouri,Sergio Giralt,Marcos de Lima,Yvonne Hsu,S. Ghosh,Joyce Neumann,Borje S. Andersson,Muzaffar H. Qazilbash,Sharon R. Hymes,Stella K. Kim,Richard E. Champlin,Michele L. Donato +18 more
TL;DR: Objective responses were observed in a substantial number of patients with both skin and visceral chronic GVHD failing corticosteroids and other immunosuppression, and response to ECP and platelet count at initiation of therapy were the strongest predictors of nonrelapse mortality (NRM) on univariate analysis.
Journal ArticleDOI
Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial
Amrita Krishnan,Marcelo C. Pasquini,Brent R. Logan,Edward A. Stadtmauer,David H. Vesole,Edwin P. Alyea,Joseph H. Antin,Raymond L. Comenzo,Stacey Goodman,Parameswaran Hari,Ginna G. Laport,Muzaffar H. Qazilbash,Scott D. Rowley,Firoozeh Sahebi,George Somlo,Dan T. Vogl,Daniel J. Weisdorf,Marian Ewell,Juan Wu,Nancy L. Geller,Mary M. Horowitz,Sergio Giralt,David G. Maloney +22 more
TL;DR: Non-myeloablative allogeneic HSCT after autologous HSCT is not more effective than tandem autologously HSCT for patients with standard-risk multiple myeloma and further enhancement of the graft versus myelomas effect and reduction in transplant-related mortality are needed.
Journal ArticleDOI
Improved Early Outcomes Using a T Cell Replete Graft Compared with T Cell Depleted Haploidentical Hematopoietic Stem Cell Transplantation
Stefan O. Ciurea,Victor E. Mulanovich,Rima M. Saliba,Ulas D. Bayraktar,Ying Jiang,Roland L. Bassett,Sa Wang,Marina Konopleva,Marcelo Fernandez-Vina,Nivia Montes,Doyle Bosque,Julianne Chen,Gabriela Rondon,Gheath Alatrash,Amin M. Alousi,Qaiser Bashir,Martin Korbling,Muzaffar H. Qazilbash,Simrit Parmar,Elizabeth J. Shpall,Yago Nieto,Chitra Hosing,Partow Kebriaei,Issa F. Khouri,Uday R. Popat,Marcos de Lima,Richard E. Champlin +26 more
TL;DR: Improved reconstitution of T cell subsets and a lower rate of infection were observed in the TCR group, indicating that a TCR graft followed by effective control of GVHD posttransplantation may lower NRM and improve survival after haploidentical SCT.
Journal ArticleDOI
Similar transplantation outcomes for acute myeloid leukemia and myelodysplastic syndrome patients with haploidentical versus 10/10 human leukocyte antigen-matched unrelated and related donors.
Antonio Di Stasi,Denái R. Milton,LM Poon,Amir Hamdi,Gabriela Rondon,Julianne Chen,Sai Ravi Pingali,Marina Konopleva,Piyanuch Kongtim,Amin M. Alousi,Muzaffar H. Qazilbash,Sairah Ahmed,Qaiser Bashir,Gheath Alatrash,Betul Oran,Chitra Hosing,Partow Kebriaei,Uday R. Popat,Elizabeth J. Shpall,Dean A. Lee,Marcos de Lima,Katayoun Rezvani,Issa F. Khouri,Richard E. Champlin,Stefan O. Ciurea +24 more
TL;DR: It is suggested that haploidentical donors can safely extend transplantation for AML/MDS patients without an HLA-matched donor, and prospective studies comparing haploIDENTical and MUD transplantation are warranted.